For example, patients already receiving a statin (or in whom statin treatment is clearly indicated/not indicated based on changes in their cardiovas- cular risk profile or clinical status) would not require follow- up LDL-C measurements because the results would not alter management. Similarly, as the link between LDL-C and adverse clinical outcomes is less robust in people with CKD than in people with normal GFR, the value of measuring LDL-C to assess prognosis is unclear. There is no direct evidence that following on-treatment lipid levels will improve clinical outcomes or encourage adherence to statin therapy. However, some patients may prefer to know their lipid levels during follow-up, or may increase their adherence to statin treatment in response to feedback about these levels. In the judgment of the Work Group, these considerations favor an ungraded statement. 